Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Current Assets (2021 - 2025)

Indivior Pharmaceuticals (INDV) has 3 years of Current Assets data on record, last reported at $827.0 million in Q4 2024.

  • For Q4 2024, Current Assets fell 34.21% year-over-year to $827.0 million; the TTM value through Dec 2024 reached $827.0 million, down 34.21%, while the annual FY2024 figure was $827.0 million, 34.21% down from the prior year.
  • Current Assets reached $827.0 million in Q4 2024 per INDV's latest filing, down from $1.3 billion in the prior quarter.
  • Across five years, Current Assets topped out at $1.4 billion in Q4 2021 and bottomed at $827.0 million in Q4 2024.
  • Average Current Assets over 3 years is $1.2 billion, with a median of $1.3 billion recorded in 2023.
  • The widest YoY moves for Current Assets: up 34.21% in 2024, down 34.21% in 2024.
  • A 3-year view of Current Assets shows it stood at $1.4 billion in 2021, then dropped by 12.95% to $1.3 billion in 2023, then crashed by 34.21% to $827.0 million in 2024.
  • Per Business Quant database, its latest 3 readings for Current Assets were $827.0 million in Q4 2024, $1.3 billion in Q4 2023, and $1.4 billion in Q4 2021.